The total number of records retrieved from this search are 68. Click on ID to see further detail.

ID	Virus name	Virus strain	Virus genome type	Virus family	Virus genome modification	Virus alone	Virus in combination with drug/radiation	Immune gene insertion in viral genome	Source of cell line	Origin of cell line	Cell line	Concentration of cell line	In-vitro toxicity	Assay	In-vitro virus concentration	In-vitro result	Model organism	In-vivo virus concentration	In-vivo toxicity	In-vivo result	Mode of delivery	Pathway induced	Immunogenic effect	Clinical trial	PMID
IDOV_717	Virus nameAvian influenza A virus	Virus strainH7N3 NS1-77	Virus genome typeRNA	Virus familyOrthomyxoviridae	Virus genome modificationMutations were introduced within the IAV NS1 gene to create a truncated protein of 77 aa (NS1-77)	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman pancreatic cancer cell line	Cell lineBxPC-3	Concentration of cell lineNA	In-vitro toxicityNA	AssayImmunoassay detection	In-vitro virus concentration0.001 MOI	In-vitro result130% cancer cell death (calculated as relative to mock-infected)	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectUp-regulation of IFN-aplha	Clinical trialNA	PMID27417501
IDOV_721	Virus nameAvian influenza A virus	Virus strainH7N3	Virus genome typeRNA	Virus familyOrthomyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman pancreatic cancer cell line	Cell lineBxPC-3	Concentration of cell lineNA	In-vitro toxicityNA	AssayImmunoassay detection	In-vitro virus concentration0.001 MOI	In-vitro result148% cancer cell death (calculated as relative to mock-infected)	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectUp-regulation of IFN-aplha	Clinical trialNA	PMID27417501
IDOV_1408	Virus nameParovirus	Virus strainH-1PV	Virus genome typeDNA	Virus familyParoviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationVirus strain in combination with norfloxacin (25 microgram/ml)	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman pancreatic adenocarcinoma cell line	Cell lineBxPC-3	Concentration of cell lineNA	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.5 MOI	In-vitro result70% cell survival	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis, activation of caspase 3	Immunogenic effectNA	Clinical trialNA	PMID19301953
IDOV_1409	Virus nameParovirus	Virus strainH-1PV	Virus genome typeDNA	Virus familyParoviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationVirus strain in combination with norfloxacin (25 microgram/ml)	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman pancreatic adenocarcinoma cell line	Cell lineBxPC-3	Concentration of cell lineNA	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result30% cell survival	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis, activation of caspase 3	Immunogenic effectNA	Clinical trialNA	PMID19301953
IDOV_2278	Virus nameVesicular stomatitis virus	Virus strainwild type	Virus genome typeRNA	Virus familyRhabdoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell linePancreatic ductal adeonocarcinoma cell line	Cell lineBxPC-3	Concentration of cell line80% confluent monolayer	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result60% cell survival after 5 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectDownregulation of IFN-Gamma	Clinical trialNA	PMID22238308
IDOV_2292	Virus nameVesicular stomatitis virus	Virus strainVSV-Delta-M51-GFP	Virus genome typeRNA	Virus familyRhabdoviridae	Virus genome modificationDeletion of M51 gene and insertion of GFP gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell linePancreatic ductal adeonocarcinoma cell line	Cell lineBxPC-3	Concentration of cell line80% confluent monolayer	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result80% cell survival after 5 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectDownregulation of IFN-Gamma	Clinical trialNA	PMID22238308
IDOV_2306	Virus nameVesicular stomatitis virus	Virus strainVSV-p1-GFP	Virus genome typeRNA	Virus familyRhabdoviridae	Virus genome modificationInsertion of P gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell linePancreatic ductal adeonocarcinoma cell line	Cell lineBxPC-3	Concentration of cell line80% confluent monolayer	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result70% cell survival after 5 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectDownregulation of IFN-Gamma	Clinical trialNA	PMID22238308
IDOV_2320	Virus nameVesicular stomatitis virus	Virus strainSev-GFP	Virus genome typeRNA	Virus familyRhabdoviridae	Virus genome modificationInsertion of GFP gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell linePancreatic ductal adeonocarcinoma cell line	Cell lineBxPC-3	Concentration of cell line80% confluent monolayer	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result100% cell survival after 5 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectDownregulation of IFN-Gamma	Clinical trialNA	PMID22238308
IDOV_2334	Virus nameVesicular stomatitis virus	Virus strainRSV-GFP	Virus genome typeRNA	Virus familyRhabdoviridae	Virus genome modificationInsertion of GFP gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell linePancreatic ductal adeonocarcinoma cell line	Cell lineBxPC-3	Concentration of cell line80% confluent monolayer	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result100% cell survival after 5 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectDownregulation of IFN-Gamma	Clinical trialNA	PMID22238308
IDOV_2348	Virus nameVesicular stomatitis virus	Virus strainwild type	Virus genome typeRNA	Virus familyRhabdoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell linePancreatic ductal adeonocarcinoma cell line	Cell lineBxPC-3	Concentration of cell line80% confluent monolayer	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.01 MOI	In-vitro result100% cell survival after 5 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectDownregulation of IFN-Gamma	Clinical trialNA	PMID22238308
IDOV_2362	Virus nameVesicular stomatitis virus	Virus strainVSV-Delta-M51-GFP	Virus genome typeRNA	Virus familyRhabdoviridae	Virus genome modificationDeletion of M51 gene and insertion of GFP gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell linePancreatic ductal adeonocarcinoma cell line	Cell lineBxPC-3	Concentration of cell line80% confluent monolayer	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.01 MOI	In-vitro result100% cell survival after 5 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectDownregulation of IFN-Gamma	Clinical trialNA	PMID22238308
IDOV_2376	Virus nameVesicular stomatitis virus	Virus strainVSV-p1-GFP	Virus genome typeRNA	Virus familyRhabdoviridae	Virus genome modificationInsertion of P gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell linePancreatic ductal adeonocarcinoma cell line	Cell lineBxPC-3	Concentration of cell line80% confluent monolayer	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.01 MOI	In-vitro result100% cell survival after 5 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectDownregulation of IFN-Gamma	Clinical trialNA	PMID22238308
IDOV_2390	Virus nameVesicular stomatitis virus	Virus strainSev-GFP	Virus genome typeRNA	Virus familyRhabdoviridae	Virus genome modificationVirus expressing GFP gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell linePancreatic ductal adeonocarcinoma cell line	Cell lineBxPC-3	Concentration of cell line80% confluent monolayer	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.01 MOI	In-vitro result100% cell survival after 5 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectDownregulation of IFN-Gamma	Clinical trialNA	PMID22238308
IDOV_2404	Virus nameVesicular stomatitis virus	Virus strainRSV-GFP	Virus genome typeRNA	Virus familyRhabdoviridae	Virus genome modificationVirus expressing GFP gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell linePancreatic ductal adeonocarcinoma cell line	Cell lineBxPC-3	Concentration of cell line80% confluent monolayer	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.01 MOI	In-vitro result100% cell survival after 5 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectDownregulation of IFN-Gamma	Clinical trialNA	PMID22238308
IDOV_3404	Virus nameVaccinia virus	Virus strainGLV-1h68	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of three gene beta-glucouronidase, galactosidase and GFP	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman pancreatic adenocarcinoma cell line	Cell lineBxPC-3	Concentration of cell line4.0E+4 cells per well	In-vitro toxicityNA	AssaySRB assay	In-vitro virus concentration0.001 MOI	In-vitro resultNo cell killing after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28607950
IDOV_3405	Virus nameVaccinia virus	Virus strainGLV-1h68	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of three gene beta-glucouronidase, galactosidase and GFP	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman pancreatic adenocarcinoma cell line	Cell lineBxPC-3	Concentration of cell line4.0E+4 cells per well	In-vitro toxicityNA	AssaySRB assay	In-vitro virus concentration0.005 MOI	In-vitro resultNo cell killing after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28607950
IDOV_3406	Virus nameVaccinia virus	Virus strainGLV-1h68	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of three gene beta-glucouronidase, galactosidase and GFP	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman pancreatic adenocarcinoma cell line	Cell lineBxPC-3	Concentration of cell line4.0E+4 cells per well	In-vitro toxicityNA	AssaySRB assay	In-vitro virus concentration0.01 MOI	In-vitro resultNo cell killing after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28607950
IDOV_3407	Virus nameVaccinia virus	Virus strainGLV-1h68	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of three gene beta-glucouronidase, galactosidase and GFP	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman pancreatic adenocarcinoma cell line	Cell lineBxPC-3	Concentration of cell line4.0E+4 cells per well	In-vitro toxicityNA	AssaySRB assay	In-vitro virus concentration0.05 MOI	In-vitro result35% cell killing after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28607950
IDOV_3408	Virus nameVaccinia virus	Virus strainGLV-1h68	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of three gene beta-glucouronidase, galactosidase and GFP	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman pancreatic adenocarcinoma cell line	Cell lineBxPC-3	Concentration of cell line4.0E+4 cells per well	In-vitro toxicityNA	AssaySRB assay	In-vitro virus concentration0.1 MOI	In-vitro result30% cell killing after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28607950
IDOV_3424	Virus nameVaccinia virus	Virus strainGLV-1h68	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of three gene beta-glucouronidase, galactosidase and GFP	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with gemcitabine (2 × 10⁻² micromolar) after 1 hour	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman pancreatic adenocarcinoma cell line	Cell lineBxPC-3	Concentration of cell line4.0E+4 cells per well	In-vitro toxicityNA	AssaySRB assay	In-vitro virus concentration0.01 MOI	In-vitro result75% of the tumor cell mass remain after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28607950
IDOV_3425	Virus nameVaccinia virus	Virus strainGLV-1h68	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of three gene beta-glucouronidase, galactosidase and GFP	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with gemcitabine (2 × 10⁻² micromolar) after 24 hour	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman pancreatic adenocarcinoma cell line	Cell lineBxPC-3	Concentration of cell line4.0E+4 cells per well	In-vitro toxicityNA	AssaySRB assay	In-vitro virus concentration0.01 MOI	In-vitro result75% of the tumor cell mass remain after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28607950
IDOV_3432	Virus nameVaccinia virus	Virus strainGLV-1h68	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of three gene beta-glucouronidase, galactosidase and GFP	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with nab-palcitaxel (1 × 10⁻² micromolar) after 1 hour	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman pancreatic adenocarcinoma cell line	Cell lineBxPC-3	Concentration of cell line4.0E+4 cells per well	In-vitro toxicityNA	AssaySRB assay	In-vitro virus concentration0.01 MOI	In-vitro result25% of the tumor cell mass remain after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28607950
IDOV_3433	Virus nameVaccinia virus	Virus strainGLV-1h68	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of three gene beta-glucouronidase, galactosidase and GFP	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with nab-palcitaxel (1 × 10⁻² micromolar) after 24 hour	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman pancreatic adenocarcinoma cell line	Cell lineBxPC-3	Concentration of cell line4.0E+4 cells per well	In-vitro toxicityNA	AssaySRB assay	In-vitro virus concentration0.01 MOI	In-vitro result50% of the tumor cell mass remain after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28607950
IDOV_3440	Virus nameVaccinia virus	Virus strainGLV-1h68	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of three gene beta-glucouronidase, galactosidase and GFP	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with nab-palcitaxel (2.5 nM)and gemcitabine (5 nM)	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman pancreatic adenocarcinoma cell line	Cell lineBxPC-3	Concentration of cell line4.0E+4 cells per well	In-vitro toxicityNA	AssaySRB assay	In-vitro virus concentration0.01 MOI	In-vitro result70% of the tumor cell mass remain after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28607950
IDOV_3441	Virus nameVaccinia virus	Virus strainGLV-1h68	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of three gene beta-glucouronidase, galactosidase and GFP	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with nab-palcitaxel (2.5 nM)and gemcitabine (5 nM)	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman pancreatic adenocarcinoma cell line	Cell lineBxPC-3	Concentration of cell line4.0E+4 cells per well	In-vitro toxicityNA	AssaySRB assay	In-vitro virus concentration0.03 MOI	In-vitro result60% of the tumor cell mass remain after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28607950
IDOV_3442	Virus nameVaccinia virus	Virus strainGLV-1h68	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of three gene beta-glucouronidase, galactosidase and GFP	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with nab-palcitaxel (2.5 nM)and gemcitabine (5 nM)	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman pancreatic adenocarcinoma cell line	Cell lineBxPC-3	Concentration of cell line4.0E+4 cells per well	In-vitro toxicityNA	AssaySRB assay	In-vitro virus concentration0.05 MOI	In-vitro result52% of the tumor cell mass remain after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28607950
IDOV_3443	Virus nameVaccinia virus	Virus strainGLV-1h68	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of three gene beta-glucouronidase, galactosidase and GFP	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with nab-palcitaxel (2.5 nM)and gemcitabine (5 nM)	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman pancreatic adenocarcinoma cell line	Cell lineBxPC-3	Concentration of cell line4.0E+4 cells per well	In-vitro toxicityNA	AssayCTB assay	In-vitro virus concentration0.01 MOI	In-vitro result50% cell viability after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28607950
IDOV_3444	Virus nameVaccinia virus	Virus strainGLV-1h68	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of three gene beta-glucouronidase, galactosidase and GFP	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with nab-palcitaxel (2.5 nM)and gemcitabine (5 nM)	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman pancreatic adenocarcinoma cell line	Cell lineBxPC-3	Concentration of cell line4.0E+4 cells per well	In-vitro toxicityNA	AssayCTB assay	In-vitro virus concentration0.03 MOI	In-vitro result40% cell viability after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28607950
IDOV_3445	Virus nameVaccinia virus	Virus strainGLV-1h68	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of three gene beta-glucouronidase, galactosidase and GFP	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with nab-palcitaxel (2.5 nM)and gemcitabine (5 nM)	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman pancreatic adenocarcinoma cell line	Cell lineBxPC-3	Concentration of cell line4.0E+4 cells per well	In-vitro toxicityNA	AssayCTB assay	In-vitro virus concentration0.05 MOI	In-vitro result30% cell viability after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28607950
IDOV_3753	Virus nameVaccinia virus	Virus strainvv-smac	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of smac and gpt gene in TK	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineType culture collection of china	Origin of cell lineHuman pancreatic cancer cell line	Cell lineBxPC-3	Concentration of cell line5.0E+3 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.0001 MOI	In-vitro result100% cell survival after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induce apoptosis in cancer cell	Immunogenic effectNA	Clinical trialNA	PMID30365143
IDOV_3754	Virus nameVaccinia virus	Virus strainvv-smac	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of smac and gpt gene in TK	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineType culture collection of china	Origin of cell lineHuman pancreatic cancer cell line	Cell lineBxPC-3	Concentration of cell line5.0E+3 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.001 MOI	In-vitro result100% cell survival after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induce apoptosis in cancer cell	Immunogenic effectNA	Clinical trialNA	PMID30365143
IDOV_3755	Virus nameVaccinia virus	Virus strainvv-smac	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of smac and gpt gene in TK	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineType culture collection of china	Origin of cell lineHuman pancreatic cancer cell line	Cell lineBxPC-3	Concentration of cell line5.0E+3 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.01 MOI	In-vitro result98% cell survival after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induce apoptosis in cancer cell	Immunogenic effectNA	Clinical trialNA	PMID30365143
IDOV_3756	Virus nameVaccinia virus	Virus strainvv-smac	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of smac and gpt gene in TK	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineType culture collection of china	Origin of cell lineHuman pancreatic cancer cell line	Cell lineBxPC-3	Concentration of cell line5.0E+3 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result20% cell survival after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induce apoptosis in cancer cell	Immunogenic effectNA	Clinical trialNA	PMID30365143
IDOV_3757	Virus nameVaccinia virus	Virus strainvv-smac	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of smac and gpt gene in TK	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineType culture collection of china	Origin of cell lineHuman pancreatic cancer cell line	Cell lineBxPC-3	Concentration of cell line5.0E+3 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration2 MOI	In-vitro result100% cell killing after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induce apoptosis in cancer cell	Immunogenic effectNA	Clinical trialNA	PMID30365143
IDOV_3758	Virus nameVaccinia virus	Virus strainvv-smac	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of smac and gpt gene in TK	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineType culture collection of china	Origin of cell lineHuman pancreatic cancer cell line	Cell lineBxPC-3	Concentration of cell line5.0E+3 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration3 MOI	In-vitro result100% cell killing after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induce apoptosis in cancer cell	Immunogenic effectNA	Clinical trialNA	PMID30365143
IDOV_3767	Virus nameVaccinia virus	Virus strainvv-smac	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of smac and gpt gene in TK	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with gemcitabine (1 micromolar)	Immune gene insertion in viral genomeNo	Source of cell lineType culture collection of china	Origin of cell lineHuman pancreatic cancer cell line	Cell lineBxPC-3	Concentration of cell line5.0E+3 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.1 MOI	In-vitro result60% cell viability after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induce apoptosis in cancer cell	Immunogenic effectNA	Clinical trialNA	PMID30365143
IDOV_3768	Virus nameVaccinia virus	Virus strainvv-smac	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of smac and gpt gene in TK	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with gemcitabine (1 micromolar)	Immune gene insertion in viral genomeNo	Source of cell lineType culture collection of china	Origin of cell lineHuman pancreatic cancer cell line	Cell lineBxPC-3	Concentration of cell line5.0E+3 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.5 MOI	In-vitro result50% cell viability after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induce apoptosis in cancer cell	Immunogenic effectNA	Clinical trialNA	PMID30365143
IDOV_3769	Virus nameVaccinia virus	Virus strainvv-smac	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of smac and gpt gene in TK	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with gemcitabine (5 micromolar)	Immune gene insertion in viral genomeNo	Source of cell lineType culture collection of china	Origin of cell lineHuman pancreatic cancer cell line	Cell lineBxPC-3	Concentration of cell line5.0E+3 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.1 MOI	In-vitro result40% cell viability after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induce apoptosis in cancer cell	Immunogenic effectNA	Clinical trialNA	PMID30365143
IDOV_3770	Virus nameVaccinia virus	Virus strainvv-smac	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of smac and gpt gene in TK	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with gemcitabine (5 micromolar)	Immune gene insertion in viral genomeNo	Source of cell lineType culture collection of china	Origin of cell lineHuman pancreatic cancer cell line	Cell lineBxPC-3	Concentration of cell line5.0E+3 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.5 MOI	In-vitro result30% cell viability after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induce apoptosis in cancer cell	Immunogenic effectNA	Clinical trialNA	PMID30365143
IDOV_4126	Virus nameAdenovirus	Virus strainAduPARE1A	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationAddition of E1A gene upstream of uPAR promoter	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with drug Gemcitabine (0.01 ng/ml)	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman pancreatic cancer cell line	Cell lineBxPC-3	Concentration of cell line3.0E+3 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration100 vp/cell	In-vitro result80% cell survival	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induce apoptosis process leads to cancer cell death	Immunogenic effectNA	Clinical trialNA	PMID26227809
IDOV_4127	Virus nameAdenovirus	Virus strainAduPARE1A	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationAddition of E1A gene upstream of uPAR promoter	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with drug Gemcitabine (1 ng/ml)	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman pancreatic cancer cell line	Cell lineBxPC-3	Concentration of cell line3.0E+3 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1000 vp/cell	In-vitro result50% cell survival	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induce apoptosis process leads to cancer cell death	Immunogenic effectNA	Clinical trialNA	PMID26227809
IDOV_4128	Virus nameAdenovirus	Virus strainAduPARE1A	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationAddition of E1A gene upstream of uPAR promoter	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with drug Gemcitabine (10 ng/ml)	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman pancreatic cancer cell line	Cell lineBxPC-3	Concentration of cell line3.0E+3 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration10000 vp/cell	In-vitro result20% cell survival	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induce apoptosis process leads to cancer cell death	Immunogenic effectNA	Clinical trialNA	PMID26227809
IDOV_4129	Virus nameAdenovirus	Virus strainAduPARE1A	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationAddition of E1A gene upstream of uPAR promoter	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with drug Gemcitabine (100 ng/ml)	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman pancreatic cancer cell line	Cell lineBxPC-3	Concentration of cell line3.0E+3 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration100000 vp/cell	In-vitro result100% cell killing	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induce apoptosis process leads to cancer cell death	Immunogenic effectNA	Clinical trialNA	PMID26227809
IDOV_4130	Virus nameAdenovirus	Virus strainAduPARE1A	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationAddition of E1A gene upstream of uPAR promoter	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with drug Gemcitabine (1000 ng/ml)	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman pancreatic cancer cell line	Cell lineBxPC-3	Concentration of cell line3.0E+3 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1000000 vp/cell	In-vitro result100% cell killing	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induce apoptosis process leads to cancer cell death	Immunogenic effectNA	Clinical trialNA	PMID26227809
IDOV_4131	Virus nameAdenovirus	Virus strainAduPARE1A	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationAddition of E1A gene upstream of uPAR promoter	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman pancreatic cancer cell line	Cell lineBxPC-3	Concentration of cell line3.0E+3 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration100 vp/cell	In-vitro result100% cell survival	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induce apoptosis process leads to cancer cell death	Immunogenic effectNA	Clinical trialNA	PMID26227809
IDOV_4132	Virus nameAdenovirus	Virus strainAduPARE1A	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationAddition of E1A gene upstream of uPAR promoter	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman pancreatic cancer cell line	Cell lineBxPC-3	Concentration of cell line3.0E+3 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1000 vp/cell	In-vitro result85% cell survival	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induce apoptosis process leads to cancer cell death	Immunogenic effectNA	Clinical trialNA	PMID26227809
IDOV_4133	Virus nameAdenovirus	Virus strainAduPARE1A	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationAddition of E1A gene upstream of uPAR promoter	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman pancreatic cancer cell line	Cell lineBxPC-3	Concentration of cell line3.0E+3 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration10000 vp/cell	In-vitro result35% cell survival	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induce apoptosis process leads to cancer cell death	Immunogenic effectNA	Clinical trialNA	PMID26227809
IDOV_4134	Virus nameAdenovirus	Virus strainAduPARE1A	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationAddition of E1A gene upstream of uPAR promoter	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman pancreatic cancer cell line	Cell lineBxPC-3	Concentration of cell line3.0E+3 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration100000 vp/cell	In-vitro result20% cell survival	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induce apoptosis process leads to cancer cell death	Immunogenic effectNA	Clinical trialNA	PMID26227809
IDOV_4135	Virus nameAdenovirus	Virus strainAduPARE1A	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationAddition of E1A gene upstream of uPAR promoter	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman pancreatic cancer cell line	Cell lineBxPC-3	Concentration of cell line3.0E+3 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1000000 vp/cell	In-vitro result100% cell killing	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induce apoptosis process leads to cancer cell death	Immunogenic effectNA	Clinical trialNA	PMID26227809
IDOV_4330	Virus nameAlphavirus	Virus strainM1	Virus genome typeRNA	Virus familyTogaviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman pancreas adenocarcinoma	Cell lineBxPC-3	Concentration of cell line4000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration10 pfu	In-vitro result98.8 % cell viability after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedActivation of cAMP signalling leads to induced expression of antiviral factors, severe ER stress and cell apoptosis	Immunogenic effectNA	Clinical trialNA	PMID26373347
IDOV_5072	Virus nameAdenovirus	Virus strainZD-55-TRAIl-IETD-smac	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationAddition of TRAIL and smac gene via IETD linker	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing TRAIL gene	Source of cell lineShanghai cell collection	Origin of cell lineHuman pancreatic cancer cell line	Cell lineBxPC-3	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result100% cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis	Immunogenic effectInduction of Interferon related gene expression	Clinical trialNA	PMID28440486
IDOV_5073	Virus nameAdenovirus	Virus strainZD-55-TRAIl-IETD-smac	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationAddition of TRAIL and smac gene via IETD linker	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing TRAIL gene	Source of cell lineShanghai cell collection	Origin of cell lineHuman pancreatic cancer cell line	Cell lineBxPC-3	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration2 MOI	In-vitro result98% cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis	Immunogenic effectInduction of Interferon related gene expression	Clinical trialNA	PMID28440486
IDOV_5074	Virus nameAdenovirus	Virus strainZD-55-TRAIl-IETD-smac	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationAddition of TRAIL and smac gene via IETD linker	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing TRAIL gene	Source of cell lineShanghai cell collection	Origin of cell lineHuman pancreatic cancer cell line	Cell lineBxPC-3	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration4 MOI	In-vitro result70% cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis	Immunogenic effectInduction of Interferon related gene expression	Clinical trialNA	PMID28440486
IDOV_5075	Virus nameAdenovirus	Virus strainZD-55-TRAIl-IETD-smac	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationAddition of TRAIL and smac gene via IETD linker	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing TRAIL gene	Source of cell lineShanghai cell collection	Origin of cell lineHuman pancreatic cancer cell line	Cell lineBxPC-3	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration8 MOI	In-vitro result60% cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis	Immunogenic effectInduction of Interferon related gene expression	Clinical trialNA	PMID28440486
IDOV_5076	Virus nameAdenovirus	Virus strainZD-55-TRAIl-IETD-smac	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationAddition of TRAIL and smac gene via IETD linker	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing TRAIL gene	Source of cell lineShanghai cell collection	Origin of cell lineHuman pancreatic cancer cell line	Cell lineBxPC-3	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration16 MOI	In-vitro result55% cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis	Immunogenic effectInduction of Interferon related gene expression	Clinical trialNA	PMID28440486
IDOV_5077	Virus nameAdenovirus	Virus strainZD-55-TRAIl-IETD-smac	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationAddition of TRAIL and smac gene via IETD linker	Virus aloneYes	Virus in combination with drug/radiationVirus in combination with SNS032 5ng/ml	Immune gene insertion in viral genomeVirus expressing TRAIL gene	Source of cell lineShanghai cell collection	Origin of cell lineHuman pancreatic cancer cell line	Cell lineBxPC-3	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result55% cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis	Immunogenic effectInduction of Interferon related gene expression	Clinical trialNA	PMID28440486
IDOV_5078	Virus nameAdenovirus	Virus strainZD-55-TRAIl-IETD-smac	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationAddition of TRAIL and smac gene via IETD linker	Virus aloneYes	Virus in combination with drug/radiationVirus in combination with SNS032 10ng/ml	Immune gene insertion in viral genomeVirus expressing TRAIL gene	Source of cell lineShanghai cell collection	Origin of cell lineHuman pancreatic cancer cell line	Cell lineBxPC-3	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration2 MOI	In-vitro result45% cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis	Immunogenic effectInduction of Interferon related gene expression	Clinical trialNA	PMID28440486
IDOV_5079	Virus nameAdenovirus	Virus strainZD-55-TRAIl-IETD-smac	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationAddition of TRAIL and smac gene via IETD linker	Virus aloneYes	Virus in combination with drug/radiationVirus in combination with SNS032 20ng/ml	Immune gene insertion in viral genomeVirus expressing TRAIL gene	Source of cell lineShanghai cell collection	Origin of cell lineHuman pancreatic cancer cell line	Cell lineBxPC-3	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration4 MOI	In-vitro result30% cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis	Immunogenic effectInduction of Interferon related gene expression	Clinical trialNA	PMID28440486
IDOV_5080	Virus nameAdenovirus	Virus strainZD-55-TRAIl-IETD-smac	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationAddition of TRAIL and smac gene via IETD linker	Virus aloneYes	Virus in combination with drug/radiationVirus in combination with SNS032 40ng/ml	Immune gene insertion in viral genomeVirus expressing TRAIL gene	Source of cell lineShanghai cell collection	Origin of cell lineHuman pancreatic cancer cell line	Cell lineBxPC-3	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration8 MOI	In-vitro result20% cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis	Immunogenic effectInduction of Interferon related gene expression	Clinical trialNA	PMID28440486
IDOV_5081	Virus nameAdenovirus	Virus strainZD-55-TRAIl-IETD-smac	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationAddition of TRAIL and smac gene via IETD linker	Virus aloneYes	Virus in combination with drug/radiationVirus in combination with SNS032 80ng/ml	Immune gene insertion in viral genomeVirus expressing TRAIL gene	Source of cell lineShanghai cell collection	Origin of cell lineHuman pancreatic cancer cell line	Cell lineBxPC-3	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration16 MOI	In-vitro result10% cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis	Immunogenic effectInduction of Interferon related gene expression	Clinical trialNA	PMID28440486
IDOV_5559	Virus nameSindbis virus	Virus strainAR339	Virus genome typeRNA	Virus familyTogaviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman pancreatic cell line	Cell lineBxPC-3	Concentration of cell line1.0E+5 cells per well	In-vitro toxicityNA	AssayNA	In-vitro virus concentration1 MOI	In-vitro resultSignificant death of cancer cell line after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis by virus infection	Immunogenic effectNA	Clinical trialNA	PMIDUS7270812B2
IDOV_5564	Virus nameReovirus	Virus strainwild type	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman pancreatic cell line	Cell lineBxPC-3	Concentration of cell line1.0E+5 cells per well	In-vitro toxicityNA	AssayNA	In-vitro virus concentration1 MOI	In-vitro resultSignificant death of cancer cell line after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis by virus infection	Immunogenic effectNA	Clinical trialNA	PMIDUS7270812B2
IDOV_5569	Virus nameSindbis virus	Virus strainAR339	Virus genome typeRNA	Virus familyTogaviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationSindbis virus in combination with Reovirus	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman pancreatic cell line	Cell lineBxPC-3	Concentration of cell line1.0E+5 cells per well	In-vitro toxicityNA	AssayNA	In-vitro virus concentration1 MOI	In-vitro resultEnhancer cytolytic effect in combination after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis by virus infection	Immunogenic effectNA	Clinical trialNA	PMIDUS7270812B2
IDOV_5575	Virus nameSindbis virus	Virus strainAR339	Virus genome typeRNA	Virus familyTogaviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman pancreatic cell line	Cell lineBxPC-3	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismNude mice xenografted subcutaneously for BxPC3	In-vivo virus concentration1.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume reduced to below 2.0 cm after 10 weeks	Mode of deliveryIntratumoral	Pathway inducedInduction of apoptosis by virus infection	Immunogenic effectNA	Clinical trialNA	PMIDUS7270812B2
IDOV_5576	Virus nameReovirus	Virus strainwild type	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman pancreatic cell line	Cell lineBxPC-3	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismNude mice xenografted subcutaneously for BxPC3	In-vivo virus concentration1.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume reduced to below 3.0 cm after 10 weeks	Mode of deliveryIntratumoral	Pathway inducedInduction of apoptosis by virus infection	Immunogenic effectNA	Clinical trialNA	PMIDUS7270812B2
IDOV_5577	Virus nameSindbis virus	Virus strainAR339	Virus genome typeRNA	Virus familyTogaviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationSindbis virus in combination with Reovirus	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman pancreatic cell line	Cell lineBxPC-3	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismNude mice xenografted subcutaneously for BxPC3	In-vivo virus concentration1.0E+6 pfu	In-vivo toxicityNA	In-vivo resultComplete reduction in tumor volume after 10 weeks	Mode of deliveryIntratumoral	Pathway inducedInduction of apoptosis by virus infection	Immunogenic effectNA	Clinical trialNA	PMIDUS7270812B2
IDOV_5578	Virus nameSindbis virus	Virus strainAR339	Virus genome typeRNA	Virus familyTogaviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman pancreatic cell line	Cell lineBxPC-3	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismNude mice xenografted subcutaneously for MIAPaCa-2	In-vivo virus concentration1.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume reduced to below 5.0 cm after 12 weeks	Mode of deliveryIntratumoral	Pathway inducedInduction of apoptosis by virus infection	Immunogenic effectNA	Clinical trialNA	PMIDUS7270812B2
IDOV_5579	Virus nameReovirus	Virus strainwild type	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman pancreatic cell line	Cell lineBxPC-3	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismNude mice xenografted subcutaneously for MIAPaCa-2	In-vivo virus concentration1.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume reduced to below 4.0 cm after 12 weeks	Mode of deliveryIntratumoral	Pathway inducedInduction of apoptosis by virus infection	Immunogenic effectNA	Clinical trialNA	PMIDUS7270812B2